Immuno-C data

BIME (Salt Lake City) announced findings from an ongoing trial in 20 healthy volunteers, reporting that 70 percent of the group showed a rise in CD4 counts after 10 days on the product (p=0.006). The rise ranged from a 7 to an 88 percent increase, with an average increase of 30 percent.

Counts remained elevated in 63 percent of volunteers 10 days after ceasing the treatment (p=0.046). ...